CAR-T's Next Frontier: Cell-Free Exosomes vs. Solid Tumor Barriers
CAR-T stalls in solid tumors due to CRS, poor stromal penetration, and costly manufacturing. Cell-free CAR-exosomes offer a cell-free approach with a distinct preclinical safety profile — but donor selection and potency validation remain key pain points. Integrated engineering bridges the gap. CAR-T cell therapy has transformed hematologic cancer treatment — yet clinical activity in...
0 Commenti 0 condivisioni 18 Views 0 Anteprima
Join JoyLife.in | Earn Money Online with Friends & Fun https://joylife.in